Bayer appointment
This article was originally published in The Tan Sheet
Executive Summary
Barbara Korberly named VP-clinical research & medical affairs activities for the Morristown, N.J.-based R&D unit, Bayer Consumer Care announces April 14. She also will lead the firm's aspirin cardio-prevention projects; Bayer recently filed a citizen petition with the FDA requesting clearance to label aspirin with claims for primary prevention of myocardial infarction (1"The Tan Sheet" Feb. 17, 2003, p. 3). Korberly joins Bayer from Pharmacia, where she served as head of global medical...
You may also be interested in...
Aspirin MI Primary Prevention Labeling Urged In Bayer Citizen Petition
Aspirin therapy led to a statistically significant 32% reduction in first myocardial infarctions among over 55,000 subjects evaluated in a meta-analysis of five primary prevention studies conducted by Bayer Consumer Care
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.